Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q3 FY22 results · Oct–Dec 2021
Cohance Lifesciences reported revenue from operations of ₹391.59 crore (up 42.4% from Q3 FY21) and net profit of ₹160.07 crore (up 40.9% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 391.59 | 274.93 | +42.4% | 300.99 | +30.1% |
| Other income | 64.69 | 4.84 | 13x | 5.04 | 13x |
| Total income | 456.27 | 279.78 | +63.1% | 306.03 | +49.1% |
| Profit before tax | 239.46 | 131.50 | +82.1% | 116.46 | +105.6% |
| Net profit for the period | 160.07 | 113.63 | +40.9% | 96.98 | +65.0% |
| EPS, basic (₹) | 6.29 | 4.46 | +41.0% | 3.81 | +65.1% |
| Net margin (%) | 40.9 | 41.3 | 32.2 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 391.59 | 274.93 | +42.4% | 300.99 | +30.1% |
| Other income | 9.27 | 4.84 | +91.5% | 38.34 | −75.8% |
| Total income | 400.86 | 279.78 | +43.3% | 339.32 | +18.1% |
| Profit before tax | 184.05 | 131.51 | +40.0% | 149.76 | +22.9% |
| Net profit for the period | 137.00 | 97.63 | +40.3% | 115.20 | +18.9% |
| EPS, basic (₹) | 5.38 | 3.84 | +40.1% | 4.53 | +18.8% |
| Net margin (%) | 35.0 | 35.5 | 38.3 |
Consolidated
- Filed with BSE
- 09 Feb 2022, 11:46 IST
- Board meeting
- 08 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Feb 2022, 11:46 IST
- Board meeting
- 08 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE